The last week shaped up to be a historic one for the cannabis industry. But as impressive as last week was, this week is shaping up to be even bigger. That's because you can bank on one recurring situation that inspires the titans of industries to try and outdo each other.
More than $42 billion is spent annually on medical and psychiatric care. And with treatments like opioids increasingly out of favor, Americans - especially veterans suffering from PTSD - are looking for safe, reliable alternatives. And cannabis more than any other substance is ready to fill that void.
With the biggest opponent to cannabis out of the way, the federal government has an easier path to pro-cannabis measures. That will open up the floodgates for publicly traded cannabis firms, especially those operating in the United States.
Election Day 2018 marked another resounding victory for cannabis. After the polls closed, Michigan became the 10th state to fully legalize cannabis, while Utah and Missouri joined 31 others that have already legalized it for medical purposes. More than half of the country now has access to some form of legal marijuana thanks to this virtual “green sweep.” And right now, you have the opportunity to take this momentum all the way to the bank.
Recently, we shared one of our favorite plays in cannabis - a company we’ve nicknamed the “Landlord of Cannabis.” Three things stood out to us - It’s profitable, It’s paying a dividend…and more importantly, its already providing profits for those who followed our advice.
On November 6, voters in four states will cast their ballots on new cannabis legalization measures that would add millions to the growing majority of American living in states where it is legal to purchase cannabis. In the process, voters will bolster the bottom line of the best cannabis firms on the market.
When downturns hit a cannabis stock, that can be a good thing - It creates opportunity following the immediacy of the bad news. Even investing legends will tell you that it's a fool's errand trying to pick the exact lowest price as the only time to get in on a stock.
The first-ever legally approved cannabis-based drug became available to patients in the United States recently. It's a true game-changer. But it may find some stiff competition from products that aren't being reviewed by the FDA.
It's time to add two more cannabis names to the NYSE scoreboard. This week, two of the big five Canadian producers join their fellow colleagues in migrating to a massive U.S. exchange - a trend our Executive Director isn't expecting to stop anytime soon. But that doesn't mean investors should rush out and snap up shares. Instead, he's got his eyes on a few other up-and-comers that offer even greater potential.